Inhibitory effect of curcumin on the Al(III)-induced Aβ42 aggregation and neurotoxicity in vitro

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 8, 2012, Pages 1207-1215

  Jiang, Teng ^a   Zhi, Xiu Ling ^a   Zhang, Yue Hong ^a   Pan, Luan Feng ^a   Zhou, Ping ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Aggregate morphology; Alzheimer's disease; Fibrillation inhibitor; Protein conformation

Indexed keywords

ALUMINUM; AMYLOID; AMYLOID BETA PROTEIN[1-42]; CURCUMIN; THIOFLAVINE;

ARTICLE; ATOMIC FORCE MICROSCOPY; CIRCULAR DICHROISM; CONTROLLED STUDY; FLUORESCENCE; IN VITRO STUDY; INHIBITION KINETICS; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION;

ALUMINUM; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CIRCULAR DICHROISM; CURCUMIN; MICROSCOPY, ATOMIC FORCE; NEUROTOXICITY SYNDROMES; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; THIAZOLES;

EID: 84861155036     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.04.015     Document Type: Article

References (56)

1. Barnham K.J., Smith D.G., Cappai R. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Bba-Biomembranes 2007, 1768:1976-1990.
2. Pike C.J., Walencewicz A.J., Glabe C.G., Cotman C.W. Invitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 1991, 563:311-314.
3. Cummings J.L., Vinters H.V., Cole G.M., Khachaturian Z.S. Alzheimer's disease-etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology 1998, 51:S2-S17.
4. Chen Y.R., Ni C.L., Shi H.P., Yu H.M., Chang Y.C. Folding stability of amyloid-beta 40 monomer is an important determinant of the nucleation kinetics in fibrillization. FASEB J. 2011, 25:1390-1401.
5. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
6. Raussens V., Cerf E., Gustot A., Goormaghtigh E., Ruysschaert J.M. High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 2011, 25:1585-1595.
7. Bieschke J., Russ J., Friedrich R.P., Ehrnhoefer D.E., Wobst H., Neugebauer K., Wanker E.E. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7710-7715.
8. Zatta P., Lucchini R., van Rensburg S.J., Taylor A. The role of metals in neurodegenerative processes: aluminum, manganese, and zinc. Brain Res. Bull. 2003, 62:15-28.
9. Exley C., House E., Collingwood J., Khan A., Korchazkina O., Berthon G. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of A beta(42) in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 2004, 6:291-301.
10. Zatta P., Ricchelli F., Drago D., Filippi B., Tognon G. Aluminum-triggered structural modifications and aggregation of beta-amyloids. Cell. Mol. Life Sci. 2005, 62:1724-1733.
11. Exley C. Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of A beta(42) in senile plaque cores in Alzheimer's disease. J. Alzheimers Dis. 2006, 10:173-177.
12. Nayak P. Aluminum: impacts and disease. Environ. Res. 2002, 89:101-115.
13. Drago D., Bettella M., Bolognin S., Cendron L., Scancar J., Milacic R., Ricchelli F., Casini A., Messori L., Tognon G., Zatta P. Potential pathogenic role of beta-amyloid(1-42)-aluminum complex in Alzheimer's disease. Int. J. Biochem. Cell Biol. 2008, 40:731-746.
14. Sakamoto T., Saito H., Ishii K., Takahashi H., Tanabe S., Ogasawara Y. Aluminum inhibits proteolytic degradation of amyloid beta peptide by cathepsin D: a potential link between aluminum accumulation and neuritic plaque deposition. FEBS Lett. 2006, 580:6543-6549.
15. Savory J., Exley C., Forbes W.F., Huang Y., Joshi J.G., Kruck T., McLachlan D.R.C., Wakayama I. Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?. J. Toxicol. Environ. Health 1996, 48:615-635.
16. Clauberg M., Joshi J.G. Regulation of serine protease activity by aluminum-implications for Alzheimer-disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:1009-1012.
17. Pratico D., Uryu K., Sung S., Tang S., Trojanowski J.Q., Lee V.M.Y. Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB J. 2002, 16:1138-1140.
18. Zatta P., Hegde M.L., Bharathi P., Suram A., Venugopal C., Jagannathan R., Poddar P., Srinivas P., Sambamurti K., Rao K.J., Scancar J., Messori L., Zecca L. Challenges associated with metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 2009, 17:457-468.
19. Rodriguez-Rodriguez C., de Groot N.S., Rimola A., Alvarez-Larena A., Lloveras V., Vidal-Gancedo J., Ventura S., Vendrell J., Sodupe M., Gonzalez-Duarte P. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J. Am. Chem. Soc. 2009, 131:1436-1451.
20. Li H.T., Lin D.H., Luo X.Y., Zhang F., Ji L.N., Du H.N., Song G.Q., Hu J., Zhou J.W., Hu H.Y. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. FEBS J. 2005, 272:3661-3672.
21. Kelloff G.J., Crowell J.A., Hawk E.T., Steele V.E., Lubet R.A., Boone C.W., Covey J.M., Doody L.A., Omenn G.S., Greenwald P., Hong W.K., Parkinson D.R., Bagheri D., Baxter G.T., Blunden M., Doeltz M.K., Eisenhauer K.M., Johnson K., Knapp G.G., Longfellow D.G., Malone W.F., Nayfield S.G., Seifried H.E., Swall L.M., Sigman C.C. Clinical development plans for cancer chemopreventive agents. J. Cell. Biochem. 1996, 72-321.
22. Galvin J.E., Pandey N., Strider J., Nolan W.C., Yan S.X. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008, 115:479-489.
23. Mishra S., Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann. Indian Acad. Neurol. 2008, 11:13-19.
24. Lim G.P., Chu T., Yang F.S., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
25. Garcia-Alloza M., Borrelli L.A., Rozkalne A., Hyman B.T., Bacskai B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 2007, 102:1095-1104.
26. Priyadarsini K.I., Barik A., Mishra B., Shen L., Mohan H., Kadam R.M., Dutta S., Zhang H.Y. Evaluation of a new copper(II)-curcumin complex as superoxide dismutase mimic and its free radical reactions. Free Radic. Biol. Med. 2005, 39:811-822.
27. Zhao X.Z., Jiang T., Wang L., Yang H., Zhang S., Zhou P. Interaction of curcumin with Zn(II) and Cu(II) ions based on experiment and theoretical calculation. J. Mol. Struct. 2010, 984:316-325.
28. Xu D.H., Mei X.T., Xu S.K., Zheng Y.P., Xu S.B. Gastroprotective and antidepressant effects of a new zinc(II)-curcumin complex in rodent models of gastric ulcer and depression induced by stresses. Pharmacol. Biochem. Behav. 2011, 99:66-74.
29. Youdim M.B.H., Mandel S., Amit T., Bar-Am O. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol. 2007, 82:348-360.
30. Jiang T., Wang L., Zhang S., Sun P.C., Ding C.F., Chu Y.Q., Ping Z. Interaction of curcumin with Al(III) and its complex structures based on experiments and theoretical calculations. J. Mol. Struct. 2011, 1004:163-173.
31. Vajragupta O., Boonchoong P., Watanabe H., Tohda M., Kummasud N., Sumanont Y. Manganese complexes of curcumin and its derivatives: evaluation for the radical scavenging ability and neuroprotective activity. Free Radic. Biol. Med. 2003, 35:1632-1644.
32. Aggarwal B.B., Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008, 267:133-164.
33. Aggarwal B.B., Anand P., Kunnumakkara A.B., Newman R.A. Bioavailability of curcumin: problems and promises. Mol. Pharmaceutics 2007, 4:807-818.
34. Lou H.X., Liu A.C., Zhao L.X., Fan P.H. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J. Pharmaceut. Biomed. 2006, 40:720-727.
35. Sahoo S.K., Mohanty C. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation. Biomaterials 2010, 31:6597-6611.
36. Aggarwal B.B., Anand P., Thomas S.G., Kunnumakkara A.B., Sundaram C., Harikumar K.B., Sung B., Tharakan S.T., Misra K., Priyadarsini I.K., Rajasekharan K.N. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol. 2008, 76:1590-1611.
37. Streltsov V.A., Titmuss S.J., Epa V.C., Barnham K.J., Masters C.L., Varghese J.N. The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease. Biophys. J. 2008, 95:3447-3456.
38. Sierks M.R., Liu R., Barkhordarian H., Emadi S., Park C.B. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol. Dis. 2005, 20:74-81.
39. Biancalana M., Koide S. Molecular mechanism of thioflavin-T binding to amyloid fibrils. Bba-Proteins Proteomics 2010, 1804:1405-1412.
40. Krebs M.R.H., Bromley E.H.C., Donald A.M. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J. Struct. Biol. 2005, 149:30-37.
41. Ulrih N.P., Barry C.H., Fink A.L. Impact of Tyr to Ala mutations on alpha-synuclein fibrillation and structural properties. Bba-Mol. Basis Dis. 2008, 1782:581-585.
42. Fasman G.D. Aluminum and Alzheimer's disease: model studies. Coord. Chem. Rev. 1996, 149:125-165.
43. Miura T., Suzuki K., Kohata N., Takeuchi H. Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry-Us 2000, 39:7024-7031.
44. Akitt J.W., Gessner W. Al-27 nuclear magnetic-resonance investigations of highly alkaline aluminate solutions. J. Chem. Soc. Dalton 1984, 147-148.
45. Besseling N.A.M., Lyklema J. Molecular thermodynamics of hydrophobic hydration. J. Phys. Chem. B 1997, 101:7604-7611.
46. Klunk W.E., Pettegrew J.W., Abraham D.J. Quantitative-evaluation of Congo Red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 1989, 37:1273-1281.
47. Yang F.S., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
48. Romhanyi G. Selective differentiation between amyloid and connective tissue structures based on collagen specific topo-optical staining reaction with Congo Red. Virchows Arch. A 1971, 354:209-222.
49. Sakono M., Zako T. Amyloid oligomers: formation and toxicity of A beta oligomers. FEBS J. 2010, 277:1348-1358.
50. Valle-Delgado J.J., Alfonso-Prieto M., de Groot N.S., Ventura S., Samitier J., Rovira C., Fernandez-Busquets X. Modulation of A beta(42) fibrillogenesis by glycosaminoglycan structure. FASEB J. 2010, 24:4250-4261.
51. LeVine H. The challenge of inhibiting A beta polymerization. Curr. Med. Chem. 2002, 9:1121-1133.
52. Tortia F.M., Hatcher H., Planalp R., Cho J., Torti S.V. Curcumin: from ancient medicine to current clinical trials. Cell. Mol. Life Sci. 2008, 65:1631-1652.
53. Rao K.S.J., Gupta V.B., Anitha S., Hegde M.L., Zecca L., Garruto R.M., Ravid R., Shankar S.K., Stein R., Shanmugavelu P. Aluminium in Alzheimer's disease: are we still at a crossroad?. Cell. Mol. Life Sci. 2005, 62:143-158.
54. Cannata-Andia J.B. Reconsidering the importance of long-term low-level aluminum exposure in renal failure patients. Semin. Dial. 2001, 14:5-7.
55. Yokel R.A. The toxicology of aluminum in the brain: a review. Neurotoxicology 2000, 21:813-828.
56. Reinke C.M., Breitkreutz J., Leuenberger H. Aluminium in over-the-counter drugs-risks outweigh benefits?. Drug Saf. 2003, 26:1011-1025.